杨帆, 赖沙毅, 王红. 糖尿病患者经皮冠状动脉介入术后氯吡格雷抵抗的临床观察[J]. 心脏杂志, 2010, 22(3): 390-392.
    引用本文: 杨帆, 赖沙毅, 王红. 糖尿病患者经皮冠状动脉介入术后氯吡格雷抵抗的临床观察[J]. 心脏杂志, 2010, 22(3): 390-392.
    Clinical observations of platelet aggregation in patients with type II diabetes undergoing percutaneous coronary intervention with clopidogrel treatment[J]. Chinese Heart Journal, 2010, 22(3): 390-392.
    Citation: Clinical observations of platelet aggregation in patients with type II diabetes undergoing percutaneous coronary intervention with clopidogrel treatment[J]. Chinese Heart Journal, 2010, 22(3): 390-392.

    糖尿病患者经皮冠状动脉介入术后氯吡格雷抵抗的临床观察

    Clinical observations of platelet aggregation in patients with type II diabetes undergoing percutaneous coronary intervention with clopidogrel treatment

    • 摘要: 目的: 探讨Ⅱ型糖尿病患者经皮冠状动脉介入术后氯吡格雷抵抗现象。方法: 入院急性冠脉综合征(ACS)患者46例,其中糖尿病患者11例,非糖尿病患者35例,予氯吡格雷负荷量300 mg,继予75 mg/d维持,在服用氯吡格雷前,服药后2、4、6、24、48与30 d取血,测定5 μmol/L二磷酸腺苷(ADP)诱导的血小板聚集率,分析两组间临床特征、血小板抑制率的差异。结果: 糖尿病患者11例中氯吡格雷抵抗的发生率为55%,高于非糖尿病患者26%(P<0.05)。结论: 在经PCI治疗的ACS并发Ⅱ型糖尿病患者中氯吡格雷抵抗的发生率高于非糖尿病患者。

       

      Abstract: AIM: To examine clopidogrel resistance among patients with type II diabetes undergoing percutaneous coronary intervention (PCI) on clopidogrel treatment. METHODS: Forty six patients (11 diabetic and 35 nondiabetic patients) with acute coronary syndrome (ACS) who had undergone PCI were treated with clopidogrel (300 mg loading dose followed by a dose of 75 mg/day). Platelet aggregation function was assessed before and 2, 4, 6, 24, 48 and 30 days after clopidogrel treatment. Platelet aggregation and characteristics between groups were compared. RESULTS: The ratio of clopidogrel resistance was much higher in diabetic patients (55%) than in nondiabetic patients (26%) (P<0.05). CONCLUSION: Diabetic subjects undergoing PCI have a higher ratio of clopidogrel resistance compared with nondiabetic subjects.

       

    /

    返回文章
    返回